Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL27P4 (ribosomal protein L27 pseudogene 4) is classified as a processed pseudogene, meaning it is a noncoding genomic sequence that shares homology with the functional ribosomal protein L27 gene but does not code for a functional protein[3][5]. Unlike its parent gene, RPL27, which produces a ribosomal protein important for ribosome structure and function[1][4], RPL27P4 is considered nonfunctional and does not participate in the synthesis of proteins or other cellular processes[3][5][12]. Pseudogenes like RPL27P4 are widespread in the human genome and typically arise by reverse transcription and genomic integration of mRNA from functional genes; only rarely do some pseudogenes retain partial regulatory activity or function, which is not documented for RPL27P4 in current literature[3][6]. Therefore, it is not regarded as a therapeutic target and has no known physiological or pathological relevance, drug interactions, or biomarker roles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L27 pseudogene 4 (RPL27P4).